My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 133

    1.

    Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.

    [No authors listed]

    Ann Intern Med. 2001 Apr 17;134(8):S-96. No abstract available. PMID: 11324633 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

    Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.

    Ann Intern Med. 2001 Apr 17;134(8):629-36.PMID: 11304102 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The kidney in cardiovascular disease.

    Kasiske BL.

    Ann Intern Med. 2001 Apr 17;134(8):707-9. No abstract available. PMID: 11304109 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.

    Mann JF.

    Presse Med. 2005 Oct 22;34(18):1303-8. Review.PMID: 16269994 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    [ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events]

    Scheen AJ, Krzesinski JM.

    Rev Med Liege. 2008 Apr;63(4):213-9. French. PMID: 18575077 [PubMed - indexed for MEDLINE]Related articles

    6.

    The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.

    Hoogwerf BJ, Young JB.

    Cleve Clin J Med. 2000 Apr;67(4):287-93.PMID: 10780101 [PubMed - indexed for MEDLINE]Related articles

    7.

    The HOPE Study (Heart Outcomes Prevention Evaluation).

    Sleight P.

    J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.PMID: 11967789 [PubMed - indexed for MEDLINE]Related articles

    8.

    Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.

    Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S.

    Am J Cardiovasc Drugs. 2002;2(3):157-62. Review.PMID: 14727978 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effect of long-term therapy with ramipril in high-risk women.

    Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation.

    J Am Coll Cardiol. 2002 Aug 21;40(4):693-702.PMID: 12204499 [PubMed - indexed for MEDLINE]Related articles

    10.

    ACE inhibitors and high-risk patients.

    Myers KA.

    CMAJ. 2000 Aug 8;163(3):327. No abstract available. PMID: 10951738 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.

    Anderson VR, Perry CM, Robinson DM.

    Am J Cardiovasc Drugs. 2006;6(6):417-32. Review.PMID: 17192135 [PubMed - indexed for MEDLINE]Related articles

    12.

    From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.

    Yusuf S.

    Am J Cardiol. 2002 Jan 24;89(2A):18A-25A; discussion 25A-26A.PMID: 11835907 [PubMed - indexed for MEDLINE]Related articles

    13.

    [The HOPE Study. What does it contribute to general practice?]

    Mann J, Sleight P.

    MMW Fortschr Med. 2000 Nov 23;142(47):28-32. German. PMID: 11143776 [PubMed - indexed for MEDLINE]Related articles

    14.

    Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?

    Hammett DC, MacFadyen JC.

    Can Fam Physician. 2000 Apr;46:821-3. No abstract available. PMID: 10790814 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.

    [No authors listed]

    Cardiovasc J Afr. 2008 Mar-Apr;19(2):108-9; discussion 109-10. No abstract available. PMID: 18516357 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.

    Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S; HOPE/HOPE-TOO Study Investigators.

    Circulation. 2005 Aug 30;112(9):1339-46.PMID: 16129815 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Ramipril: a review of its use in the prevention of cardiovascular outcomes.

    Warner GT, Perry CM.

    Drugs. 2002;62(9):1381-405. Review.PMID: 12076194 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results]

    Scheen AJ.

    Rev Med Liege. 2000 Feb;55(2):121-4. French. PMID: 10769584 [PubMed - indexed for MEDLINE]Related articles

    19.

    Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

    Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators.

    Am Heart J. 2004 Jul;148(1):52-61.PMID: 15215792 [PubMed - indexed for MEDLINE]Related articles

    20.

    The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

    Unger T.

    Am J Cardiol. 2003 May 22;91(10A):28G-34G. Review.PMID: 12781906 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity